Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum

Before you go, we thought you'd like these...
Before you go close icon

Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NAS: OPXA) , a company developing Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 6th Annual European Life Science CEO Forum on Tuesday, March 5, 2013, at 2:30 p.m. CET. The conference will be held at the Hilton Zurich Airport Hotel in Zurich, Switzerland.

About Opexa
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company's leading therapy, Tcelna™, is a personalized cellular immunotherapy treatment that is in late stage clinical development for MS. Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.


For more information, please visit the Company's website at www.opexatherapeutics.com.



Opexa Therapeutics, Inc.
Neil K. Warma
President & CEO
281-775-0600
nwarma@opexatherapeutics.com
or
Investor Relations:
The Trout Group
Adam Cutler
646-378-2936
opexa@troutgroup.com

KEYWORDS:   United States  Europe  North America  Texas  Switzerland

INDUSTRY KEYWORDS:

The article Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners